The impact of eicosanoids on compliance, cardiovascular performance, and coagulation during hemodialysis.
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004573:Electrolytes / Q000097:blood; D011464:Epoprostenol / Q000009:adverse effects / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D016285:Iloprost; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010974:Platelet Aggregation / Q000187:drug effects*; D006435:Renal Dialysis; D014508:Urea / Q000097:blood
D002317:Cardiovascular Agents; D004573:Electrolytes; D014508:Urea; D006493:Heparin; D003404:Creatinine; D011464:Epoprostenol; D016285:Iloprost